Tuberculosis Vaccine Initiative
The Tuberculosis Vaccine Initiative (TBVI) is a Product Development Partnership (PDP) that facilitates the discovery, development and delivery of safe, effective and affordable tuberculosis (TB) vaccines. TBVI was established as a non-profit foundation in 2008 and is based in The Netherlands.
Governance
[edit]The highest decision-making body of TBVI is its Governance Board, which helps direct strategic planning, and oversees the organisation´s operational effectiveness and financial performance. The Chair of TBVI’s Governance Board is Prof. Michel Kazatchkine, a French physician, diplomat and former director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Governance Board is supported by an Advisory Committee, which provides advice on strategic and scientific issues related to R&D, resource mobilisation and external relations.
TBVI’s operations are headed by the Executive Director who is responsible for the implementation of TBVI’s activitie,. Since March 2024, the Executive Director is Prof. Ole F. Olesen.
Research and development activities
[edit]TBVI’s activities are centred around four principal areas:
- Technical support services
- Knowledge generation, exchange and networking
- Product identification, design, development and management
- Resource mobilisation
TBVI’s R&D activities are implemented in collaboration with a more than 50 R&D partners, consisting of vaccine discoverers and developers from academia, research institutes and private industry, and mostly based in Europe and sub-Saharan Africa.
TBVI has coordinated several R&D consortia funded by the European Union (EU), including the TBVAC-Horizon and ITHEMYC consortia.[1]
TBVI has created TB Vaccine Development Pathway, which gives independent, and standardised technical and state-of-the-art scientific advice on TB vaccine development. TBVI has also served as secretariat for the Global TB Vaccine Partnership (GTBVP) .[2]
Further reading
[edit]Brennan, M. J., Thole J. (2012), ‘Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade’, Tuberculosis, 92(1): pp. S6-S13, http://www.tuberculosisjournal.com/article/S1472-9792(12)70005-7/fulltext (accessed 20 Jul. 2017).[3]
European Parliament (2011), ‘European Parliament resolution of 3 February 2011 on the Tuberculosis Vaccine Initiative (TBVI),’ http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P7-TA-2011-0039&language=EN&ring=B7-2011-0089 (accessed 20 Jul. 2017).[4]
Perhaps also of interest: The status of tuberculosis vaccine development, March 2020 https://doi.org/10.1016/ S1473-3099(19)30625-5 [5]
References
[edit]- ^ "World Tuberculosis Day: EU-funded projects contributing to fighting the global tuberculosis epidemic - European Commission". hadea.ec.europa.eu. Retrieved 2025-05-22.
- ^ GTBVP. "Global Tuberculosis Vaccine Partnership". GTBVP. Retrieved 2025-05-22.
- ^ Brennan, Michael J.; Thole, Jelle (2012-03-01). "Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade". Tuberculosis. Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade. 92: S6 – S13. doi:10.1016/S1472-9792(12)70005-7. ISSN 1472-9792.
- ^ "Texts adopted - Tuberculosis Vaccine Initiative (TBVI) - Thursday, 3 February 2011". www.europarl.europa.eu. Retrieved 2025-05-22.
- ^ Schrager, Lewis K.; Vekemens, Johan; Drager, Nick; Lewinsohn, David M.; Olesen, Ole F. (2020-03-01). "The status of tuberculosis vaccine development". The Lancet Infectious Diseases. 20 (3): e28 – e37. doi:10.1016/S1473-3099(19)30625-5. ISSN 1473-3099. PMID 32014117.